Literature DB >> 17479919

Catheter-related bacteremia and multidrug-resistant Acinetobacter lwoffii.

Luciano Tega, Katia Raieta, Donatella Ottaviani, Gian Luigi Russo, Giovanni Blanco, Antonio Carraturo.   

Abstract

Entities:  

Mesh:

Year:  2007        PMID: 17479919      PMCID: PMC2725873          DOI: 10.3201/eid1302.060858

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Acinetobacter species are ubiquitous in the environment. In recent years, some species, particularly A. baumannii, have emerged as important nosocomial pathogens because of their persistence in the hospital environment and broad antimicrobial drug resistance patterns (,). They are often associated with clinical illness including bacteremia, pneumonia, meningitis, peritonitis, endocarditis, and infections of the urinary tract and skin (). These conditions are more frequently found in immunocompromised patients, in those admitted to intensive care units, or in those who have intravenous catheters, and those who are receiving mechanical ventilation (,). The role of A. baumannii in nosocomial infections has been documented (), but the clinical effect of other Acinetobacter species has not been investigated. A. lwoffii (formerly A. calcoaceticus var. lwoffii) is a commensal organism of human skin, oropharynx, and perineum that shows tropism for urinary tract mucosa (). Few cases of A. lwoffii bacteremia have been reported (,–). We report a 4-year (2002–2005) retrospective study of 10 patients with A. lwoffii bacteremia admitted to a 600-bed teaching hospital in central Italy. All 10 patients were immunocompromised; 8 had used an intravascular catheter (peripheral or central) and 2 had used a urinary catheter. Blood cultures of the patients were analyzed with the BacT/ALERT 3D system (bioMérieux, Marcy l’Etoile, France). Isolates were identified as A. lwoffii by using the Vitek 2 system and the API 20NE system (both from bioMérieux). Susceptibilities of 10 A. lwoffii isolates to 18 antimicrobial drugs were determined by the broth microdilution method, according to Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) guidelines (). The drugs tested were amikacin, ampicillin-sulbactam, aztreonam, cefepime, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, imipenem, levofloxacin, meropenem, ofloxacin, piperacillin, piperacillin-tazobactam, tetracycline, tobramycin, and trimethoprim-sulfamethoxazole. MIC was defined as the lowest drug concentration that prevented visible bacterial growth. Interpretative criteria for each drug tested were as in CLSI guidelines (). A. lwoffii resistant to >4 classes of drugs were defined as multidrug-resistant (MDR) isolates. A. lwoffii isolates were genotyped by pulsed-field gel electrophoresis (PFGE) to determine their epidemiologic relatedness. Chromosomal DNA was digested with SmaI () and analyzed with a CHEF DR II apparatus (Bio-Rad Laboratories, Hercules, CA, USA). PFGE patterns were classified as identical, similar (differed by 1–3 bands), or distinct (differed by >4 bands) (). Among the 10 A. lwoffii isolates, 6 were susceptible to all drugs except cephalosporins (cefepime, cefotaxime, ceftazidime, and ceftriaxone) and aztreonam. The other 4 isolates were MDR: 3 were susceptible only to imipenem (MICs 1–4 μg/mL), meropenem (MICs 1–2 μg/mL), and amikacin (MICs 2–4 μg/mL). The fourth MDR strain was susceptible to imipenem (MIC 2 μg/mL), meropenem (MIC 2 μg/mL), amikacin (MIC 4 μg/mL), and ciprofloxacin (MIC 1 μg/mL). Seven antimicrobial drug resistance profiles were detected (Table).
Table

Antimicrobial drug susceptibility and pulsed-field gel electrophoresis (PFGE) patterns of 10 Acinetobacter lwoffii strains, Italy, 2002–2005

No.Source*Drug†AntibiotypePFGE
ASPIPTCECTCACFATCILEOFGMTMAMTCIPMPTS
1ICURRRRRRRRRRRRRSRSSRaA
2ICURRRRRRRRRRRRRSRSSRaB
3OWRRRRRRRRRRRRRSRSSRaB
4ICURRRRRRRRSRRRRSRSSRbC
5ICUSSRSSRRRRRRSSSSSSScD
6ICURSSSRRRSSSSRRSSSSSdE
7UWSSSRRRRRSSSSSSRSSSeF
8ICUSRSRRSRRSSSSSSSSSRfG
9ICUSRSRRSRRSSSSSSSSSRfG
10MWSSSSSRSRSRRRSRSSSSgH

*ICU, intensive care unit; OW, orthopedic ward; UW, urologic ward; MW, medical ward.
†AS, ampicillin-sulbactam; PI, piperacillin; PT, piperacillin-tazobactam; CE, cefepime; CT, cefotaxime; CA, ceftazidime; CF, ceftriaxone; AT, aztreonam; CI, ciprofloxacin; LE, levofloxacin; OF, ofloxacin; GM, gentamicin; TM, tobramycin; AM, amikacin; TC, tetracycline; IP, imipenem; MP, meropenem; TS, trimethoprim-sulfamethoxazole; R, resistant; S, susceptible.

*ICU, intensive care unit; OW, orthopedic ward; UW, urologic ward; MW, medical ward.
†AS, ampicillin-sulbactam; PI, piperacillin; PT, piperacillin-tazobactam; CE, cefepime; CT, cefotaxime; CA, ceftazidime; CF, ceftriaxone; AT, aztreonam; CI, ciprofloxacin; LE, levofloxacin; OF, ofloxacin; GM, gentamicin; TM, tobramycin; AM, amikacin; TC, tetracycline; IP, imipenem; MP, meropenem; TS, trimethoprim-sulfamethoxazole; R, resistant; S, susceptible. Macrorestriction analysis of the A. lwoffii isolates identified 8 distinct PFGE types. Two MDR strains (strains 2 and 3 in the Table), which were isolated from patients in different wards, and 2 non-MDR strains (strains 8 and 9), which were isolated from patients in the same ward, had similar PFGE patterns and identical resistance phenotypes. These findings suggest nosocomial transmission. Nine of the 10 patients survived after catheter removal or treatment with appropriate antimicrobial drugs. These results confirm that catheter-related A. lwoffii bacteremia in immunocompromised hosts is associated with a low risk for death (,). This study identified A. lwoffii MDR strains that cause bacteremia in immunocompromised catheterized patients. Our data are consistent with those of previous reports on the role of catheters as the principal source of A. lwoffii infections.
  9 in total

Review 1.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

Review 2.  Treatment of multidrug resistant Acinetobacter.

Authors:  Clinton K Murray; Duane R Hospenthal
Journal:  Curr Opin Infect Dis       Date:  2005-12       Impact factor: 4.915

3.  Acinetobacter bacteraemia in a teaching hospital, 1989-1998.

Authors:  C Valero; J D. García Palomo; P Matorras; C Fernández-Mazarrasa; C González Fernández; M C. Fariñas
Journal:  Eur J Intern Med       Date:  2001-09       Impact factor: 4.487

Review 4.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

5.  Community-acquired pneumonia due to Acinetobacter lwoffii in a patient infected with the human immunodeficiency virus.

Authors:  P Domingo; R Muñoz; G Frontera; R Pericas; E Martinez
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079

6.  Epidemiological investigation of nosocomial Acinetobacter infections using arbitrarily primed PCR & pulse field gel electrophoresis.

Authors:  K Prashanth; S Badrinath
Journal:  Indian J Med Res       Date:  2005-11       Impact factor: 2.375

7.  Clinical and microbiological characteristics of bacteremia caused by Acinetobacter lwoffii.

Authors:  S C Ku; P R Hsueh; P C Yang; K T Luh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-07       Impact factor: 3.267

8.  Vascular catheter-related bloodstream infection due to Acinetobacter johnsonii (formerly Acinetobacter calcoaceticus var. lwoffi): report of 13 cases.

Authors:  H Seifert; A Strate; A Schulze; G Pulverer
Journal:  Clin Infect Dis       Date:  1993-10       Impact factor: 9.079

9.  Bacteraemia in the adult intensive care unit of a teaching hospital in Nottingham, UK, 1985-1996.

Authors:  M Crowe; P Ispahani; H Humphreys; T Kelley; R Winter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

  9 in total
  10 in total

1.  Whole-genome sequence of a multidrug-resistant clinical isolate of Acinetobacter lwoffii.

Authors:  Yongfei Hu; Wei Zhang; Hui Liang; Liping Liu; Guojun Peng; Yuanlong Pan; Xi Yang; Beiwen Zheng; George F Gao; Baoli Zhu; Hongyan Hu
Journal:  J Bacteriol       Date:  2011-07-08       Impact factor: 3.490

2.  Genes encoding OXA-134-like enzymes are found in Acinetobacter lwoffii and A. schindleri and can be used for identification.

Authors:  Jane F Turton; Rhiannon Hyde; Kate Martin; Jayesh Shah
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

3.  Incidence of Acinetobacter species other than A. baumannii among clinical isolates of Acinetobacter: evidence for emerging species.

Authors:  Jane F Turton; Jayesh Shah; Chika Ozongwu; Rachel Pike
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

4.  Acinetobacter septicus sp. nov. association with a nosocomial outbreak of bacteremia in a neonatal intensive care unit.

Authors:  Abdullah Kilic; Haijing Li; Alexander Mellmann; Ahmet C Basustaoglu; Mustafa Kul; Zeynep Senses; Hakan Aydogan; Charles W Stratton; Dag Harmsen; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2007-12-26       Impact factor: 5.948

5.  Pyogenic Liver Abscess Caused by Acinetobacter lwoffii: A Case Report.

Authors:  N Pal Singh; Tanu Sagar; Kirti Nirmal; I Rajender Kaur
Journal:  J Clin Diagn Res       Date:  2016-06-01

6.  Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo.

Authors:  Bruce L Geller; Kimberly Marshall-Batty; Frederick J Schnell; Mattie M McKnight; Patrick L Iversen; David E Greenberg
Journal:  J Infect Dis       Date:  2013-10-14       Impact factor: 5.226

7.  Acinetobacter lwoffii Peritonitis in a Patient on Automated Peritoneal Dialysis: A Case Report and Review of the Literature.

Authors:  Murat Yasar Tas; Meral Merve Oguz; Mevlut Ceri
Journal:  Case Rep Nephrol       Date:  2017-07-26

8.  Identification of Lama glama as Reservoirs for Acinetobacter lwoffii.

Authors:  Martín M Ledesma; Ailén M Díaz; Claudia Barberis; Carlos Vay; Marcela A Manghi; Juliana Leoni; Marisa S Castro; Alejandro Ferrari
Journal:  Front Microbiol       Date:  2017-03-02       Impact factor: 5.640

9.  Acinetobacter baumannii: Role in Blood Stream Infection in Neonatal Unit, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

Authors:  Enty Tjoa; Lucky Hartati Moehario; Andriansjah Rukmana; Rinawati Rohsiswatmo
Journal:  Int J Microbiol       Date:  2013-10-28

10.  Metagenomic assessment of the interplay between the environment and the genetic diversification of Acinetobacter.

Authors:  Marc Garcia-Garcera; Marie Touchon; Sylvain Brisse; Eduardo P C Rocha
Journal:  Environ Microbiol       Date:  2017-12-01       Impact factor: 5.491

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.